<2-(F-octyl)-undecyl>dimorpholinophosphoramidate | 134051-92-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: <2-(F-octyl)-undecyl>dimorpholinophosphoramidate
• 英文别名: 11-(perfluorooctyl)undecyl dimorpholinophosphate；11-(Perfluorooctyl)undecyl dimorpholinophosphinate；4-[12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,19-heptadecafluorononadecoxy(morpholin-4-yl)phosphoryl]morpholine
• CAS: 134051-92-6
• 化学式: C₂₇H₃₈F₁₇N₂O₄P
• 分子量: 808.556
• InChiKey: SIGZHCRJKAFRED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.6
• 重原子数：
  51
• 可旋转键数：
  21
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  23

反应信息

• 作为产物：
  描述：

  12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,19-Heptadecafluorononadecanol 在 三乙胺 、 三氯氧磷 作用下， 以 乙醚 为溶剂， 反应 1.0h， 生成 <2-(F-octyl)-undecyl>dimorpholinophosphoramidate
  参考文献：
  名称：

  Synthesis and preliminary data on the biocompatibility and emulsifying properties of perfluoroalkylated phosphoramidates as injectable surfactants

  摘要：

  Perfluoroalkylated dimorpholinophosphoramidates, 1-4, were synthesized in 65-80% yield by phosphorylation of the appropriate perfluoroalkylated alcohol by phosphorus oxytrichloride, followed by reaction with morpholine. Preliminary biological tests (effect on cell cultures, hemolysis of red blood cells, and acute in vivo toxicity in mice) performed on compounds 1 to 5 show that the F-alkylated derivatives 1 to 4 are better tolerated than their hydrocarbon analog 5 in spite of their higher surface activity. Where the emulsification of fluorocarbons is concerned, the incorporation of the perfluoroalkylated compounds 1 to 4 in 20% w/v F-decalin/lecithin-based emulsions results in a slight stabilizing effect (not found for the hydrocarbon analog 5), detectable only after one month of storage at 25-degrees-C. However, when used as the sole surfactant, the F-alkylated dimorpholinophosphoramidates show no emulsifying properties; this may be assigned to insufficient hydrophilicity of the dimorpholinophosphoramidate head.

  DOI：

  10.1016/0223-5234(91)90151-c

文献信息

• STABLE REVERSE AND MULTIPLE FLUOROCARBON EMULSIONS
  申请人：ALLIANCE PHARMACEUTICAL CORPORATION

  公开号：EP0788347A1

  公开（公告）日：1997-08-13
• LUNG SURFACTANT SUPPLEMENTS
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

  公开号：EP1740189A1

  公开（公告）日：2007-01-10
• Lung Surfactant Supplements
  申请人：Krafft Marie-Pierre

  公开号：US20080019926A1

  公开（公告）日：2008-01-24

  The invention relates to a method for improving the fluidity and/or the spreadability of the native lung surfactant in a human or animal in need of such treatment, wherein the human or animal is administered with a fluorocarbon composition. The invention further relates to therapeutic compositions comprising a fluorocarbon, optionally in combination with a phospholipid, and their use as lung surfactant supplements.
• US5904933A
  申请人：——

  公开号：US5904933A

  公开（公告）日：1999-05-18
• [EN] STABLE REVERSE AND MULTIPLE FLUOROCARBON EMULSIONS<br/>[FR] RE-EMULSIONS STABLES ET EMULSIONS MULTIPLES DE FLUOROCARBONE
  申请人：ALLIANCE PHARMACEUTICAL CORP.

  公开号：WO1995033447A1

  公开（公告）日：1995-12-14

  (EN) Stable reverse water-in-fluorocarbon emulsions and water-in-fluorocarbon-in-water multiple emulsions comprising the reverse fluorocarbon emulsions. The reverse emulsions comprise a continuous phase which is a highly fluorinated or perfluorinated compound, a discontinuous aqueous phase and a fluorinated surfactant or mixture of surfactants. The multiple emulsions comprise an aqueous continuous phase and a discontinuous phase comprising globules formed of aqueous droplets dispersed into a highly fluorinated or perfluorinated compound. The emulsions can contain pharmacologically active agents, and are particularly suitable for pulmonary drug delivery.(FR) Ré-émulsions stables eau dans fluorocarbone et émulsions multiples eau dans fluorocarbone dans eau, comprenant ces ré-émulsions de fluorocarbone, lesquelles comportent une phase continue qui est un composé fortement fluoré ou perfluoré, une phase aqueuse discontinue, ainsi qu'un tensioactif fluoré ou un mélange de tensioactifs. Les émulsions multiples comportent une phase aqueuse continue ainsi qu'une phase aqueuse discontinue comprenant des globules formés de gouttelettes aqueuses dispersées dans un composé fortement fluoré ou perfluoré. Ces émulsions peuvent contenir des agents actifs sur le plan pharmacologique et elles trouvent une application particulière dans l'apport de médicaments aux poumons.